info@seagull-health.com
SeagullHealth
search
Pegasys(Peginterferon alfa-2a)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Pegasys(Peginterferon alfa-2a) Instructions:Uses,Dosage, Side Effects
PEGASYS (peginterferon alfa-2a) is a long-acting form of interferon used to treat chronic viral hepatitis B and C. The drug works by stimulating the immune system, specifically targeting the body's innate immune response to inhibit viral replication. It is most commonly prescribed for adult and pediatric patients with chronic hepatitis C and chronic hepatitis B, especially in cases where other antiviral treatments are not viable. The medication can be used either in combination with other drugs, such as ribavirin, or as monotherapy in patients with contraindications to other treatments.
PEGASYS is administered via subcutaneous injections. The typical dosage for adult patients with chronic hepatitis C is 180 mcg per week, and for chronic hepatitis B, the dosage remains consistent at 180 mcg per week for 48 weeks. Pediatric dosages vary according to body surface area and genotype. Regular monitoring is essential during treatment to manage any adverse reactions, particularly neuropsychiatric, autoimmune, and infectious disorders, which can arise as side effects.
1.Chronic Hepatitis C (CHC):
1.1 In combination with other hepatitis C virus (HCV) antiviral drugs for adults with compensated liver disease;
1.2 As monotherapy for adults who have contraindications or significant intolerance to other HCV drugs;
1.3 In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease.
2.Chronic Hepatitis B (CHB):
1.1 Adults: Treatment of adults with HBeAg-positive or HBeAg-negative chronic hepatitis B who have compensated liver disease, viral replication, and liver inflammation.
1.2 Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT).
1. Adult Patients with CHC:180 mcg subcutaneously once a week. Duration of therapy depends on the HCV genotype, combination with other antiviral drugs, and the patient’s clinical response;
2. Adult Patients with CHB:180 mcg subcutaneously once a week for 48 weeks;
3. Pediatric Patients with CHC:180 mcg per 1.73 m² of body surface area (BSA) subcutaneously once a week in combination with ribavirin;
4. Pediatric Patients with CHB:180 mcg per 1.73 m² of BSA subcutaneously once a week for 48 weeks.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
